Biphasic Effect of Melanocortin Agonists on Metabolic Rate and Body Temperature  by Lute, Beth et al.
Cell Metabolism
ArticleBiphasic Effect of Melanocortin Agonists
on Metabolic Rate and Body Temperature
Beth Lute,1 William Jou,1 Dalya M. Lateef,2 Margalit Goldgof,2 Cuiying Xiao,2 Ramo´n A. Pin˜ol,2 Alexxai V. Kravitz,2
Nicole R. Miller,3 Yuning George Huang,4 Clemence Girardet,5 Andrew A. Butler,5 Oksana Gavrilova,1
and Marc L. Reitman2,*
1Mouse Metabolism Core, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA
2Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda,
MD 20892, USA
3Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA
4Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA
5Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL 33458, USA
*Correspondence: marc.reitman@nih.gov
http://dx.doi.org/10.1016/j.cmet.2014.05.021SUMMARY
The melanocortin system regulates metabolic ho-
meostasis and inflammation. Melanocortin agonists
have contradictorily been reported to both increase
and decrease metabolic rate and body temperature.
We find two distinct physiologic responses occurring
at similar doses. Intraperitoneal administration of
the nonselective melanocortin agonist MTII causes
a melanocortin-4 receptor (Mc4r)-mediated hyper-
metabolism/hyperthermia. This is preceded by a pro-
found, transient hypometabolism/hypothermia that
is preserved in mice lacking any one of Mc1r, Mc3r,
Mc4r, or Mc5r. Three other melanocortin agonists
also caused hypothermia, which is actively achieved
via seeking a cool environment, vasodilation, and
inhibition of brown adipose tissue thermogenesis.
These results suggest that the hypometabolic/hypo-
thermic effect of MTII is not due to a failure of
thermoregulation. The hypometabolism/hypother-
mia was prevented by dopamine antagonists, and
MTII selectively activated arcuate nucleus dopami-
nergic neurons, suggesting that these neurons may
contribute to the hypometabolism/hypothermia. We
propose that the hypometabolism/hypothermia is
a regulated response, potentially beneficial during
extreme physiologic stress.
INTRODUCTION
Tight and flexible control of energy homeostasis is essential for
survival, of both the individual and the species. The evolving
epidemics of obesity and type 2 diabetes are likely the result
of environmental changes interacting with genetic variation,
causing an imbalance between energy assimilation and energy
expenditure. A more complete understanding of the physiologic
control mechanisms should lead to improved therapies for
obesity and diabetes.CelThe melanocortin system helps control energy homeostasis
(Cone, 2005, 2006; Tao, 2010). Of the fivemelanocortin receptors,
Mc4r has received the most attention: mice become obese when
they express agouti, a protein inhibitor of Mc4r (Yen et al., 1994),
whenMc4r function is disrupted (Huszar et al., 1997), or when the
endogenous ligands (e.g., a-melanocyte-stimulating hormone,
a-MSH) derived from pro-opiomelanocortin are lost (Yaswen
et al., 1999). Similarly, human obesity can be caused by reduced
MC4R function (Vaisse et al., 1998; Yeo et al., 1998) or by loss of
agonist ligand (Krude et al., 1998). MC4R mutations account
for 1%–5% of extreme human obesity (Alharbi et al., 2007;
Stutzmann et al., 2008), and common variants near MC4R are
also associated with obesity (Loos et al., 2008). MC4R agonists
are being considered for the treatment of obesity, as they reduce
food intake, increase metabolic rate, and increase insulin sensi-
tivity (e.g., Kievit et al., 2013). However, MC4R agonists also
elevate blood pressure (Greenfield et al., 2009; Silva et al.,
2006) and increase erectile activity (Van der Ploeg et al., 2002).
a-MSH also binds to and activates MC1R, MC3R, and MC5R,
but not MC2R.MC1R agonism causes darkening of skin and hair
(Robbins et al., 1993) and reduces inflammation (Leoni et al.,
2010; Li and Taylor, 2008), while loss of MC1R function reduces
sensitivity to certain painful stimuli (Mogil et al., 2003, 2005).
MC3R contributes to the control of energy homeostasis (e.g.,
null mice are mildly obese; Butler et al., 2000; Chen et al.,
2000a), natriuresis (Ni et al., 2003), and inflammation, acting at
least partially onmacrophages (Getting et al., 2008). Genetic vari-
ation inMC3Rmaycontribute tohumanobesity (Fenget al., 2005;
Renquist et al., 2011). MC5R regulates exocrine secretion (Chen
et al., 1997) and inflammation (Lee and Taylor, 2013).
With the focus on melanocortins in obesity, an older, some-
times contradictory, literature investigating stress, inflammation,
and core body temperature (Tb) has received less attention. Lip-
ton and Glyn (1980) reported that a-MSH reduced rabbit rectal
temperature and found that low doses of a-MSH prevented lipo-
polysaccharide-induced fever (Catania and Lipton, 1993; Mur-
phy et al., 1983). In contrast, a-MSH increased Tb in rats (Raible
and Knickerbocker, 1993; Resch and Simpson, 1991). Much of
this Tb work was performed using nonselective ligands, such
as a-MSH and MTII (Haskell-Luevano et al., 1997), before the
identification of all five melanocortin receptors. MC4R-selectivel Metabolism 20, 333–345, August 5, 2014 ª2014 Elsevier Inc. 333
Figure 1. MTII Tb Dose Response in Lean C57BL/6J Mice
(A) Tb response to the indicated MTII dose (red) or vehicle (black, repeated in each panel) injected into chow-fed mice (mean of n = 6/group, body weight
27.1 ± 0.3 g) studied at 21C–22C. Left and right panels show the same data with different Tb axis scales to allow visualization of both effects. Every fifth SEM is
shown for visual clarity.
(B–E) Dose response curves for the nadir in Tb (B), physical activity (mean, 0–30 min) (C), peak increase in Tb (difference between the mean of 150 to 30 min
and the mean of 120–300 min) (D), and physical activity (mean, 120 to 300 min) (E) from the analyses of the data shown in (A). Activity is in arbitrary units via Mini
Mitter. *p < 0.05 versus pooled vehicle, 0.2, and 0.5 mg/kg MTII data. Data are mean ± SEM.
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MC4R contribution is also suspected (Metzger et al., 2010; Nich-
olson et al., 2007; Sinha et al., 2003, 2004).
The mouse, due to its small body size, exhibits amplified
changes in Tb and responses to manipulation of environmental
temperature (Gordon, 1993, 2012). The large Tb changes and
available genetic variants make the mouse an ideal system for
studying the thermal biology of melanocortins. While melano-
cortin agonists typically increase metabolic rate (Chen et al.,
2000b), there is also a report of a metabolic rate reduction
(Wisse et al., 2006). Here, we study the effects of melanocortin334 Cell Metabolism 20, 333–345, August 5, 2014 ª2014 Elsevier Incagonism on metabolic rate and Tb, finding divergent effects
with importance for both energy homeostasis and the control
of inflammation.
RESULTS
Biphasic Effect of Treatment with MTII on Energy
Expenditure and Tb
The nonselective melanocortin agonist, MTII, has a biphasic
effect, first decreasing and then increasing Tb in chow-fed
C57BL/6J mice (Figure 1A). These effects are in addition to the.
Figure 2. Thermogenic Effects of MTII
Treatment in Diet-Induced Obese C57BL/
6J Mice Housed at Thermoneutrality or
Room Temperature
(A) Tb, TEE, RER, and activity in DIO mice (mean
body weight, 45.6 g) treated with MTII (black cir-
cles) or vehicle (white circles) in a randomized
crossover design studied at 30C (n = 6/group).
(B) Tb, TEE, RER, and activity in the same
mice studied at 22C (n = 9/group). Data are
mean ± SEM.
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Melanocortin Hypometabolism and Hypothermiastress of handling, which initially increases both Tb and physical
activity in mice treated with either vehicle or MTII. The effective
dose 50 (ED50) for the hypothermic effect of MTII was 3.3 ±
0.5 mg/kg (Figure 1B). The hypothermia effect reached a plateau
at the highest doses (5, 10, and 20 mg/kg), with these doses ex-
hibiting a similar nadir Tb, time to nadir Tb (35 ± 1, 38 ± 3, and
37 ± 3 min), and maximum cooling rate (1.33 ± 0.08, 1.37 ±
0.08, and1.50 ± 0.12C/5 min at8–14 min after dosing). Dur-
ing hypometabolism/hypothermia, physical activity was reduced
(Figure 1C). The late Tb increase produced by MTII had an ED50
of 1.4 ± 0.5 mg/kg (Figure 1D) and was sometimes accompanied
by slight increases in physical activity (Figure 1E).
MTII’s hypothermic and hyperthermic effects in diet-induced
obese (DIO) mice (46.1 ± 0.8 g) were similar to those in the
chow-fed mice. The hypothermia ED50 was 3.3 ± 0.6 mg/kg,
and the hyperthermia ED50 was 2.0 ± 0.8 mg/kg. The nadir Tb
was 32.7 ± 0.5, 31.7 ± 0.3, and 31.4 ± 0.8C at 5, 10, and
20mg/kg, respectively, occurring at 41±3, 43±3, and42±4min.
The effects of pharmacologic agents on metabolic rate are
typically studied at thermoneutrality to neutralize the contribu-
tion of facultative thermogenesis. In DIO mice, the MTII-induced
hypothermia at thermoneutrality (30C) was truncated compared
to the effect at 22C (Figure 2). Like its effect on Tb, MTII
decreased and then increased total energy expenditure (TEE),
while it had the opposite effect (increase then decrease) on res-
piratory exchange ratio (RER, indicating a decrease then in-
crease in fractional fat oxidation). In DIO mice at 22C, the Tb
reduction was 4C, and the TEE reduction was 50% (Fig-
ure 2B). The nadir in TEE precedes that for Tb (at 23.8 ±
1.6 min for TEE versus 39.9 ± 2.8 min for Tb; p < 0.001). The
late increase in Tb and TEE and decrease in RER were seen at
both 22C and 30C.
Interestingly, hypothermia was not observed with every MTII
treatment—it was not seen after 9% of 155 injections in 65
mice. All 11 nonresponding mice that were tested more than
once did show hypothermia with previous or subsequent MTII
treatment. The hypothermic response to MTII was preserved in
the setting of a cage switch (Lee et al., 2004) (Figure S1, available
online). This suggests that stress, as caused by cage switch,
does not prevent the hypothermic response.Cell Metabolism 20, 333–34Hypothermia Generation Is an
Active Process with Reduced Heat
Generation and Ongoing Heat Loss
The physiological basis for the hypo-
metabolism/hypothermia was investi-
gated next. Brown adipose tissue (BAT)temperature is 1C higher than Tb, but at 20 min after MTII
dosing, this BAT-Tb difference was abolished. By 50 and
180 min after dosing, the BAT-Tb differential was reestab-
lished (Figures 3A–3C). The mice were cooler over their full
surface area; no preferred sites for heat loss were detected
using infrared thermography (Figure 3D). These data demon-
strate that BAT inactivation contributes to the hypothermic
effect of MTII and suggest that BAT reactivation contri-
butes to rewarming. However, rewarming occurred normally
in Ucp1/ mice (Figure 3E), suggesting that other heat-
generating mechanisms can substitute for the lack of BAT
functionality.
Next, we compared the rate of MTII-induced Tb reduction to
the rate of heat loss after death (Figure 3F). The times for Tb
to fall from 35.0C to 33.5C were 8.5 ± 1.0 and 7.3 ± 0.2 min
in two euthanasia groups, compared with 9.0 ± 1.3 min in
MTII-treated mice (not statistically different). Thus, the rate of
Tb reduction by MTII approaches that seen with cessation of
metabolism.
When mice were allowed to choose their environment after
MTII administration, the preferred environmental temperature
was5C cooler than after treatment with vehicle, and the dura-
tion of the cool preference was similar to the duration of the
hypothermia (Figure 3G). After moving to the cool region, the
mice were largely immobile. No shivering was observed. Taken
together, these data suggest that the mouse uses all available
mechanisms in order to achieve profound hypometabolism/
hypothermia.
Hypothermic Effect Attenuates with Repeated
Dosing of MTII
When MTII was administered daily for 5 days, the late increase
in Tb showed little or no attenuation, while the hypothermic
effect was greatly attenuated by the second dose and not
detectable subsequently (data not shown). The kinetics of the
attenuation were explored by injecting two doses of MTII 2 hr
apart. There was no hypothermia with the second MTII dose
(Figure S2). This suggests that MTII hypometabolism/hypo-
thermia is a time-limited response followed by an extended
refractory period.5, August 5, 2014 ª2014 Elsevier Inc. 335
Figure 3. Physiology of the Hypothermic
Response to MTII
(A–C) In chow-fed C57BL/6J mice after MTII (red)
or vehicle (black) treatment, we show Tb (A),
interscapular BAT temperature (B), and the
differential between BAT temperature and Tb (C).
Temperatures were measured at the indicated
times after dosing. Data are mean ± SEM; n = 6/
group; *p < 0.05 versus vehicle (mean weight
27.5 g).
(D) Infrared images of chow-fed mice taken 5 min
before and 20 min after vehicle or MTII treatment
using a FLIR T400 camera and analyzed using
FLIR QuickReport 1.2 SP2 for measurement of
temperatures within images.
(E) Response of Ucp1/ mice to MTII at 22C
(body weight 26.1 ± 1.6 g; n = 8–10/group;
crossover design, 8 male and 2 female). Every
tenth SEM is shown for visual clarity.
(F) Rate of heat loss in DIO mice. Mice were
euthanized by carbon dioxide (black dashed line)
or cervical dislocation (black solid line) at time 0.
As a concurrent control, live mice were adminis-
tered MTII (red). Ambient temperature was 21.6C
(data aremean ± SEM; n = 6–7/group; bodyweight
52.1 ± 1.3 g). For visual clarity, every fifth SEM is
graphed.
(G) Choice of environmental temperature. Mice on
a chow diet were treated with MTII (red) or vehicle
(black) and immediately placed in a thermal
gradient, with position monitored by video (n = 8,
crossover design). Ambient temperature was
21.6C (dashed line).
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Figure 4. MTII Effect on Blood Pressure and Heart Rate
(A–C) We measured mean arterial pressure (A), pulse pressure (as a percent of
systolic blood pressure) (B), and heart rate (C) in ambulating telemetered mice
at 22C treated with vehicle or MTII in a crossover design; n = 5–6/group. Tb
was measured just prior to MTII injection (35.5C ± 0.3C) and again at 40 min
(vehicle, 36.1C ± 0.3C; MTII, 31.1C ± 0.3C). Data are mean ± SEM.
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Hypothermia
Melanocortin activation causes an increase in blood pressure
(Greenfield et al., 2009; Hall et al., 2010; Sohn et al., 2013). How-
ever, at early times after MTII dosing we observed profound
hypotension, with a nadir arterial pressure of 109 ± 7 millimeters
of mercury (mmHg) in the vehicle group versus 38 ± 4 mmHg
after MTII (p < 0.001) (Figure 4A). Similar nadir changes were
observed in the systolic (127 ± 6 versus 48 ± 11 mmHg; p <
0.001) and diastolic (99 ± 5 versus 32 ± 8mmHg; p < 0.001) blood
pressure. The pulse pressure increased, suggesting that vasodi-
lation contributes to the hypotension (Figure 4B). The blood
pressure nadir was at 28 min (median), similar in time course
and duration to the drop in TEE. MTII treatment also decreased
heart rate, but this effect was smaller, more variable, and ofCelshorter duration than the effect on blood pressure (Figure 4C).
Interestingly, the MTII hypotension was not accompanied by
tachycardia at any time; the heart rate actually remained below
that of the vehicle-treated controls, which exhibited the ex-
pected increase due to handling stress. At later times after
MTII dosing, there was a suggestion of an increase in heart
rate but no clear increase in blood pressure.
MTII Hypometabolism and Hypermetabolism in
Melanocortin Mutant Mice
Since MTII binds four melanocortin receptors (MC1R, MC4R >
MC3R > MC5R; Haskell-Luevano et al., 1997; see also Conde-
Frieboes et al., 2012), we examined which receptors mediate
the TEE and Tb effects in chow-fed mice. An initial hypometab-
olism/hypothermia was observed in Mc1re/e,Mc3r/, Mc4r/,
and Mc5r/ mice (Figures 5A–5D). It was also observed in
Mc3r/;Mc4r/ double null mice, Avy/+ mice (Avy/+ mice have
reduced Mc1r and Mc4r signaling), andMc3r/;Avy/+mice (Fig-
ures 5E–5G). These results indicate that neither Mc1r, Mc3r,
Mc4r, nor Mc5r is individually required for the initial hypometa-
bolic/hypothermic response. The late increase in TEE and
reduction in RER (indicating increased fat oxidation) were lost
in the Mc4r/ and Mc3r/;Mc4r/ mice and retained in
Mc1re/e, Mc3r/, and Mc5r/ mice, demonstrating that these
late effects are dependent on Mc4r. These data demonstrate
that different receptors control the hypometabolism/hypother-
mia versus the hypermetabolism/hyperthermia.
To further explore receptor specificity, wemeasured the effect
of a MC1R agonist, BMS-470539 (Kang et al., 2006). While
BMS-470539 at 30 mg/kg i.p. caused hypothermia in wild-type
mice, hypothermia also occurred in Mc1re/e mice (Figures S3A
and S3B), indicating that this BMS-470539 effect does not
require MC1R. We found that the small molecule MC4R agonist
compound 2B (Guo et al., 2008) caused hypothermia and hypo-
metabolism in both wild-type and Mc4r/ mice (Figures S3C
and S3D), indicating that hypothermia/hypometabolism with
40 mg/kg intraperitoneal (i.p.) compound 2B does not require
MC4R. Another peptide melanocortin agonist, NDP-MSH
([Nle4,D-Phe7]-a-MSH) (Haskell-Luevano et al., 1997), also
caused hypothermia with doses at the high end of those reported
(Hoggard et al., 2004), and the hypothermia also occurred in
Mc3r/;Avy/+ mice (Figure S3E).
Dopamine Receptor Antagonists Block MTII
Hypometabolism/Hypothermia
To investigate possible mechanisms by which MTII causes
hypothermia, we selectively blocked neurotransmitters that
can cause hypothermia. Specifically, naloxone (10 mg/kg i.p.)
blocks mu/kappa opioid receptor-mediated hypothermia (Baker
and Meert, 2002), naltrindole (5 mg/kg i.p.) blocks delta opioid
receptor-mediated hypothermia (Rawls and Cowan, 2006),
WAY100635 (1 mg/kg subcutaneously) blocks serotonin
5-HT1A receptor-mediated hypothermia (Cryan et al., 2000;
Rawls and Cowan, 2006), and AM251 (10 mg/kg i.p.) blocks
cannabinoid-1 receptor-mediated hypothermia (McMahon and
Koek, 2007). Each inhibitor was tested by itself and had no effect
on Tb in the first hour after dosing. When dosed prior to MTII,
none of the inhibitors ameliorated MTII hypothermia (data not
shown). These data indicate that MTII hypothermia does notl Metabolism 20, 333–345, August 5, 2014 ª2014 Elsevier Inc. 337
(legend on next page)
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5-HT1A, or cannabinoid-1 receptors.
Brain-penetrant dopamine agonists cause hypothermia via
both D1-like and D2-like receptors (Carboni et al., 1986; Nunes
et al., 1991), referred to hereafter as D1 and D2. Individually,
a D1 antagonist (SCH23390, 2mg/kg i.p.) or a D2 antagonist (sul-
piride, 30 mg/kg i.p.) partially inhibited MTII hypothermia, while
the combined inhibitors completely blocked MTII hypothermia
(Figures 6A and 6B). D1/D2 combined inhibition also inhibited
MTII-induced hypometabolism (Figures 6E–6H). MTII is not
acting directly on either D1 or D2 receptors, as MTII does not
bind with high affinity to these receptors (Figure S4). Physical
activity was not affected by D2 antagonism and only modestly
inhibited by D1 antagonism. However, activity was greatly
inhibited by combined D1/D2 inhibition, irrespective of MTII
treatment (Figures 6C and 6D). Decreased physical activity typi-
cally decreases Tb; thus, the prevention of MTII hypothermia by
D1/D2 inhibition is in the opposite direction of that expected for
an activity effect. The later decrease in RER caused byMTII is not
inhibited by dopamine antagonists. Taken together, these data
demonstrate that the hypothermia caused by MTII is reversed
by D1/D2 blockers and is largely independent of physical activ-
ity. In contrast, combined D1/D2 inhibition did not ablate the
hypotensive effect of MTII, despite slight increases in mean arte-
rial pressure and reduction in pulse pressure (Figures 6I–6K).
These results mechanistically distinguish the hypometabolism/
hypothermia from the hypotension.
The hypothermic effect of the D2 agonist, quinpirole (1 mg/kg
i.p.), attenuates with daily dosing (Buck et al., 2000). However,
when given 2 hr apart, quinpirole-induced hypothermia did not
attenuate, and there was no cross-attenuation of MTII and quin-
pirole (Figure 6L). Thus, attenuation of MTII hypometabolism/
hypothermia does not appear to be a direct D2 effect.
MTII Selectively Activates Dopaminergic Neurons in the
Arcuate Nucleus
The dopamine antagonist data suggest that MTII acts via dopa-
minergic neurons to cause hypothermia/hypometabolism. To
identify such neurons, we looked in brain regions implicated
in the regulation of Tb and EE for dopaminergic (tyrosine hydrox-
ylase [TH]-immunoreactive) neurons activated (Fos-immunore-
active) at 1 hr after treatment with MTII. Of seven candidate
regions, only the arcuate nucleus showed increased Fos stain-
ing after MTII treatment in TH-immunoreactive neurons (Fig-
ure 7). Since melanocortins can act via arcuate dopaminergic
neurons to suppress prolactin secretion (Dutia et al., 2012),
we measured Fos activation in Mc3r/;Mc4r/ mice, which
presumably lack this function. In Mc3r/;Mc4r/ mice
treated with MTII, the percentage of TH-immunoreactive neu-
rons that stained for Fos, while reduced compared to wild-Figure 5. Tb, TEE, and RER Response of Melanocortin Receptor Muta
(A) Mc1r e/e (21.6 ± 0.3 g) and wild-type (23.3 ± 0.8 g) male mice (n = 6/group).
(B) Mc3r/ (27.3 ± 0.6 g) and wild-type (27.0 ± 0.5 g) male mice (n = 12/group).
(C) Mc4r/ (54.1 ± 1.0 g) and wild-type (29.3 ± 0.6 g) male and female mice (n =
(D) Mc5r/ (23.3 ± 0.6 g) and wild-type (22.3 ± 0.6 g) male mice (n = 6/group).
(E) Mc3r/;Mc4r/ (42.7 ± 1.6 g) and wild-type (25.6 ± 0.8 g) male and female
(F) Avy/+ (30.3 ± 1.5 g) and wild-type (22.5 ± 0.6 g) female mice (n = 5/group).
(G) Mc3r/; Avy/+ (37.6 ± 2.0 g, n = 5) and wild-type (28.5 ± 0.5 g, n = 9) male m
Celtype mice, was significantly greater than that of vehicle-treated
Mc3r/;Mc4r/ mice (Figure 7). These data suggest that
arcuate dopaminergic neurons may mediate the MTII-induced
hypothermia.
DISCUSSION
The current studies aimed to unravel the contradictory observa-
tions that melanocortin agonists can both increase and decrease
both metabolic rate and Tb. We found that MTII, the most
commonly used melanocortin agonist, causes hypermetabo-
lism/hyperthermia in mice, which is preceded by a transient
hypometabolism/hypothermia/hypotension, with both effects
occurring at similar doses. Immediately after MTII administra-
tion, there are dramatic reductions in metabolic rate (by
50%), Tb (by 4C), and blood pressure (by 65%) in awake
mice at room temperature. Characteristics of the hypometa-
bolic/hypothermic state include turning off BAT thermogenesis,
rapid heat loss, active seeking of a cool environment, reduced
physical activity, and no compensatory shivering. The TEE nadir
at 24 min precedes the Tb nadir at 40 min, suggesting that
hypometabolism drives the hypothermia. Thus, the hypometa-
bolism is not simply a consequence of the reduced temperature
per se causing the reduction in metabolic rate processes (known
as a ‘‘Q10’’ or temperature coefficient effect). While melanocor-
tins cause heat loss via the tail in rat (Sinha et al., 2003) and
ears in rabbit (Lipton et al., 1981), heat loss in themouse appears
generalized. Indeed, the hypotension and increased pulse
pressure suggest that vasodilation is facilitating the heat loss.
It is notable that the hypotension is not accompanied by a
compensatory tachycardia, as occurs with some causes of
hypotension, such as hypovolemia. The inactive BAT, hypoten-
sion, and lack of tachycardia are all evidence of reduced sympa-
thetic tone. These observations demonstrate that reaching the
hypothermic state is an active, coordinately regulated process,
with reduced heat generation and without induction of heat-
conserving mechanisms.
The hypometabolic/hypothermic response to MTII is pre-
served in mice lacking the function of any one of Mc1r, Mc3r,
Mc4r, or Mc5r. Three other melanocortin ligands (NDP-MSH,
compound 2B, and BMS-470539) also caused hypothermia,
and these responses were also preserved in various melanocor-
tin mutant mice, despite using doses previously believed to be
selective. Thus, the hypometabolic/hypothermic response to
MTII and other ligands appears to be mediated redundantly via
melanocortin and/or other unidentified receptors. It is notable
that the MTII ED50s for both the hypothermic and hyperthermic
responses are comparable and smaller than the 4–20 mg/kg
doses typically used (e.g., Balthasar et al., 2005; Chen et al.,
2000b; Chen et al., 2009).nt Mice to MTII
4–6/group).
mice (n = 6/ group).
ice, crossover design. Data are mean ± SEM.
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Figure 6. Role of Dopamine in Mediating the Hypothermic Response to MTII
(A–D) Wemeasured Tb (A), nadir Tb (B), activity (C), and mean activity (mean of 10–60 min) (D) in chow-fed mice (30.0 ± 0.3 g) at 22C pretreated with vehicle, D1
antagonist (SCH23390, 2 mg/kg), or D2 antagonist (sulpiride, 30 mg/kg) 15 minutes before treatment with vehicle or MTII (n = 7–8/group). Activity is in arbitrary
units via Mini Mitter.
(legend continued on next page)
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Melanocortin Hypometabolism and HypothermiaOur working model (Figure 7D) is that MTII causes hypometa-
bolism/hypothermia via dopamine neurons, possibly in the
arcuate nucleus. The dopamine acts on D1 and D2 receptors
to lower Tb. It is not known if MTII is acting directly on the dopa-
minergic neurons or on more upstream neurons. We focused
on dopamine because MTII hypothermia is inhibited by dopa-
mine antagonists, but not by other inhibitors of pharmacologic
hypothermia (antagonists of mu, kappa, and delta opioid,
5HT1A, and cannabinoid-1 receptors). Dopamine regulates Tb
in the preoptic area/anterior hypothalamus (Boulay et al., 1999;
Brown et al., 1982; Cox and Lee, 1977). It is possible that the
arcuate nucleus dopaminergic neurons that are still activated
by MTII inMc3r/;Mc4r/mice are part of the circuit between
MTII-responding cells and the hypometabolism/hypothermia.
The physical site of MTII action causing hypometabolism/
hypothermia is not known (Warne and Xu, 2013). Since hyperme-
tabolism is a centrally mediated effect, the similar ED50s for
hyperthermia and hypothermia are consistent with hypometa-
bolism/hypothermia also being a central effect. In rabbits, mela-
nocortin injection into the preoptic and septal regions (which
regulate Tb; Nakamura, 2011) inhibited fever (Feng et al., 1987;
Glyn-Ballinger et al., 1983). However, a more anatomically
diverse regulation of MTII effects has been proposed since
local MTII injections into the nucleus tractus solitarius, paraven-
tricular nucleus, rostral ventrolateral medulla, parabrachial nu-
cleus, and the retrochiasmatic area all increased Tb (Skibicka
and Grill, 2009). Mc4r reactivation in paraventricular nucleus
(PVN) neurons restores the food intake response to MTII, but
not the metabolic rate effects (Balthasar et al., 2005). Metabolic
rate and blood pressure effects of MC4R aremediated by cholin-
ergic preganglionic neurons in the dorsal motor nucleus of the
vagus and intermediolateral column (Rossi et al., 2011; Sohn
et al., 2013).
After its rapid onset, the hypothermic/hypometabolic state is
self-limited, being largely reversed by 1 hr and refractory to a
second dose of MTII. These kinetics are not a simple function
of MTII pharmacokinetics since the Tb changes are independent
of MTII dose over a 4-fold range and thus likely independent of
plasma MTII levels (MTII plasma elimination t½ is 20 min; Hat-
ziieremia et al., 2007). The intact rewarming in Ucp1/ mice
demonstrates that the backup mechanisms invoked to maintain
Tb in these mutant mice (Bal et al., 2012; Liu et al., 2003) are also
sufficient for rewarming after MTII hypothermia. These data
suggest that the hypothermic/hypometabolic response is a
triggered process of limited duration that is followed by a refrac-
tory period; the hypermetabolism does not exhibit a refractory
period.
What is the physiologic significance of the hypometabolism/
hypothermia? All five of the melanocortin receptors have anti-in-
flammatory activities (Caruso et al., 2007; Catania et al., 2004,
2010; Getting et al., 2008; Lee and Taylor, 2013; Li and Taylor,
2008). It seems plausible that the hypometabolism/hypother-
mia/hypotension effects are part of a physiologic response to(E–H) We measured Tb (E), TEE (F), RER (G), and activity (H) at 22C in chow-fed
2 mg/kg and sulpiride, 30 mg/kg) 15 minutes before treatment with vehicle or M
(I–K) We measured mean arterial pressure (I), pulse pressure (J), and heart rate (K
antagonists (SCH23390, 2 mg/kg i.p. and sulpiride, 30 mg/kg i.p.) 15 minutes be
(L) Chow-fedmice (29.2 ± 0.3 g) at 22Cwere treated with vehicle, MTII, or quinpir
Cellimit stress/inflammation and increase survival. Indeed, melano-
cortin agonism increases survival in a mouse model of multiple
organ dysfunction (Bitto et al., 2011). In humans, hypothermia
is endogenously generated in ominous clinical situations,
including severe trauma (Shafi et al., 2005) and sepsis (Clemmer
et al., 1992). Hypothermia/hypometabolism is also induced
therapeutically to improve clinical outcomes, such as with
hypoperfusion surgery (Lampe and Becker, 2011) and after
hypoxic/hypoperfusion injury (Holzer, 2010). We hypothesize
that hypometabolism/hypothermia is a conserved, organized,
and regulated physiologic response to dire situations, and not
dysregulated thermal regulation. Just as fever increases the
inflammatory response to fight infection (Mackowiak, 1998),
hypothermia puts a brake on it, with beneficial effect in some
situations.
Melanocortin hypermetabolism/hyperthermia is distinguished
from the hypometabolism/hypothermia by its timing, lack of
attenuation, and selectivity for MC4R. The metabolism/obesity
field has focused on the hypermetabolism/hyperthermia, as
this melanocortin physiology is relevant for understanding food
intake, metabolic rate, body weight and adiposity, and insulin
sensitivity. Melanocortin agonism is a potential treatment for
obesity but has been hampered by autonomic effects, including
increased blood pressure (Greenfield et al., 2009). Our observa-
tions suggest that there may be other effects of high doses of
such drugs. The hypometabolic/hypothermic and hypermeta-
bolic/hyperthermic responses are distinct physiologic pro-
cesses with distinguishable drivers and biologic effects. Further
understanding of the hypometabolic/hypothermic response
could lead to better understanding of when to use clinical hypo-
thermia, improved methods for inducing, maintaining, and
reversing clinical hypothermia, and optimized treatment of
accidental hypothermia.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 male mice (Jackson Laboratory) were singly housed at 22C, fed
NIH-07 chow (15% kcal from fat, Harlan Laboratories) or D12492 (60% kcal
from fat, Research Diets), and studied between 14 and 37 weeks of age.
Mice were maintained at 21C–22C with lights on 6 a.m.–6 p.m. Food and
water were available ad libitum, including during drug treatments and indirect
calorimetry. All animal studies were approved by the NIDDK/NIH Animal Care
and Use Committee. Mc4r/ mice (loxTB Mc4r; Mc4rtm1Lowl/J) (Balthasar
et al., 2005), Mc3r/ mice (loxTB Mc3r; Mc3rtmButl/J) (Begriche et al., 2011),
and Mc3r/;Mc4r/ mice were generated by heterozygote mating and
studied on mixed genetic backgrounds using littermates as controls. Mc1re/e
mice (81%C57BL/6J) (Robbins et al., 1993) were provided by Dr. David Fisher
(MGH). Mc5r/ mice (Chen et al., 1997) were supplied by Dr. Andrew Taylor
(Boston University Medical Center, C57BL/6J background). Avy/+ mice
(B6.C3-Avy/J) (Yen et al., 1994) and Ucp1/ (B6.129-Ucp1tm1Kz/J) (Enerba¨ck
et al., 1997) were purchased from Jackson Laboratory. Mice were studied
R7 days after any operation or prior treatment. Reuse of mice tends to reduce
physical activity levels, presumably due to acclimatization. No specific effort
was made to acclimatize mice to handling in individual experiments.mice (27.2 ± 0.3 g) pretreated with vehicle, D1and D2 antagonists (SCH23390,
TII (n = 6/group).
) in ambulating telemetered mice at 22C pretreated with vehicle or D1 and D2
fore treatment with MTII at t = 0 in a crossover design (n = 3–4/group).
ole at 0 hr and again 2 hr later, as indicated (n = 4/group). Data are mean ± SEM.
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Figure 7. MTII Activates Dopaminergic Neurons Selectively in the Arcuate Nucleus
(A and B) Immunohistochemistry for TH (green; left panel) and Fos (red; middle panel) after vehicle (A) or MTII (B) treatment of C57BL/6J mice. Scale bar
represents 100 mm in main image and 50 mm in insert. Arrowheads indicate Fos-positive TH neurons; 3V, third ventricle; ME, median eminence.
(C) Percentage of TH-immunoreactive neurons staining for Fos after vehicle or MTII administration in wild-type (n = 3/group) and Mc3r/;Mc4r/ mice (n = 4/
group). Neurons were counted in the subcommissural part of the A14 dopaminergic cell group (A14sc; 2–3 sections), preoptic part of the periventricular
hypothalamic nucleus (PVpo; 3 sections), paraventricular nucleus of the hypothalamus (PVN; 6–7 sections), anterior and intermediate part of the periventricular
hypothalamic nucleus (PVa-i; 6–7 sections), dorsomedial hypothalamic nucleus (DMH; 2–3 sections), zona incerta (ZI; 3 sections), and arcuate nucleus (Arc; 6–7
sections). The number of TH neurons per region was not statistically different between the MTII and vehicle groups, and the analyzed areas had expected
distributions of TH-immunoreactive neurons (Lookingland and Moore, 2005). Data are mean ± SEM; *p < 0.05 versus vehicle. #p < 0.05, wild-type versus
Mc3r/;Mc4r/.
(D) Actions of melanocortin agonists. Melanocortin agonists act via Mc4r to signal that the body is in an ‘‘energy replete’’ state, detectable for example as an
increase in energy expenditure and Tb during fasting. Melanocortin agonists also act likely via both melanocortin and other receptors to signal ‘‘extreme stress’’
caused by factors such as hypoxia, sepsis, and severe trauma. This triggers a time-limited set of responses, including hypometabolism and hypothermia
mediated by dopaminergic pathways and also hypotension, which appears not to occur via dopaminergic pathways.
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Drugs (Bachem for MTII; otherwise Tocris or Sigma) were administered
at 10–11 a.m. with the indicated dosing concentration, dose, route, and
vehicle: MTII (up to 2 mg/ml i.p., saline; dosed at 10 mg/kg i.p. when not
otherwise specified), NDP-MSH (100 and 400 mg/mouse i.p., saline), sulpiride
(3 mg/ml, 30 mg/kg i.p., 100% DMSO, heated to 60C, then 9 vol of saline),
SCH23390 (0.4 mg/ml, 2 mg/kg i.p., saline), quinpirole (0.1 mg/ml, 1 mg/kg
i.p., water), AM251 (1 mg/ml, 10 mg/kg per os, 100% DMSO, heated to342 Cell Metabolism 20, 333–345, August 5, 2014 ª2014 Elsevier Inc60C, then 1 vol Tween 80 and 8 vol of saline), naloxone (1 mg/ml, 10 mg/kg
i.p., saline), naltrindole (0.5 mg/ml, 5 mg/kg i.p., saline), and WAY100635
(0.1 mg/ml, 1 mg/kg s.c., water).
Tb Telemetry
Tb and activity were continuously measured by telemetry (Mini Mitter/Philips
Respironics) using ER4000 energizer/receivers, G2 E-mitters implanted intra-
peritoneally, and VitalView software with data collected each minute. The.
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Melanocortin Hypometabolism and Hypothermiahypothermia metric is the nadir of Tb at 20–50 min after melanocortin dosing.
The hyperthermia metric is the mean Tb at 120–300 min minus the mean Tb
at 150 to 30 min relative to dosing. ED50s were calculated by fitting to a
four-parameter logistic curve using SigmaPlot v.12.5. BAT temperature and
Tb were measured simultaneously in mice carrying two IPTT-300 transpon-
ders (Bio Medic Data Systems), one sutured to the omentum and the other
sutured underneath the interscapular BAT.
Blood Pressure Telemetry
Chronic ambulatory arterial blood pressure and heart rate were measured
with radio transmitters (model TA11PA-C10; Data Sciences International)
implanted during ketamine and xylazine anesthesia in the carotid artery as
described (Oppermann et al., 2009). Data were sampled for 10 s every 2 min
and processed using a model RPC-1 receiver, a 20-channel data exchange
matrix, APR-1 ambient pressure monitor, and a Data Quest ART Silver 2.3
acquisition system.
Temperature Preference Test
Mice were placed in a stainless steel pan (643 153 20 cm, length3 width 3
height) spanning two hot/cold plates such that a temperature gradient from
18C to 36C was established across the floor of the pan. Mice were placed
into this pan for 90 min, and their position was tracked with an overhead cam-
era and video tracking software (EthoVision 9.0, Noldus). The temperature
gradient was calibrated with a FLIR T400 infrared camera, and these images
were used to transform the position data into temperature.
Calorimetry
An Oxymax/CLAMS (Columbus Instruments) was used to measure Tb, energy
expenditure (O2 consumption and CO2 production), and activity by beam
break simultaneously in mice implanted with G2 E-mitters. RER is the ratio
of CO2 produced to O2 consumed. Experiments were performed at 22
C or
30C, as indicated. Sampling was typically every 13 minutes, measuring
from 12 chambers. When better time resolution was required, only six cham-
bers were studied, allowing sampling every 6 minutes.
Immunohistochemistry
Male mice were housed individually from day 7 and, during the 4 days pre-
ceding the experiment, habituated to handling and i.p. injection. On the day
of the experiment, mice received MTII (10 mg/kg, i.p.) or vehicle, returned to
their home cage and were anesthetized 60 minutes later, had their rectal tem-
perature measured, and were perfused with 10% formalin solution. Brains
were fixed for 2 hr, transferred to 30% sucrose solution for 2 days, frozen,
and sectioned (Leica SM2010R). A 1-in-3 series of coronal 40 mm sections
was incubated (overnight, room temperature, constant agitation) with anti-
bodies to TH (Millipore, MAB318; 1:1,000 dilution) and Fos (Calbiochem,
PC38; 1:7,000 dilution). After rinsing, the sections were incubated in Alexa
Fluor 488 anti-mouse and Alexa Fluor 555 anti-rabbit (1:500 dilution) for 2
hours, rinsed, and mounted using ProLong Gold Antifade medium. Images
were captured (Olympus VS120 Slide Scanner microscope) and analyzed
with OlyVIA software (v.2.6) or with a Zeiss LSM 510 confocal microscope. A
neuron was scored TH-immunoreactive only if its nucleus was visible and
surrounded by a rim of TH immunofluorescence. Anatomy was defined
according to (Franklin and Paxinos, 2008), with periventricular hypothalamic
nucleus subdivisions per Allen Mouse Brain Atlas (http://mouse.brain-map.
org/static/atlas). We did not use a stereological procedure or counting correc-
tion factor since we are testing for changes between genotype and/or treat-
ment. The percentage of MTII treatment-activated TH neurons is the number
of Fos-positive TH-immunoreactive neurons divided by the total number of
TH-immunoreactive neurons.
Statistics
Data are reported as mean ± SEM. Significance (two-tailed p < 0.05) was
determined using SigmaPlot using t test or two-way ANOVA.
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